Η παρατεταμένη χρήση Ταμοξιφένης μειώνει της υποτροπή και τη θνησιμότητα του καρκίνου του μαστού.
June 3, 2013
In women with early breast cancer, extending the duration of adjuvant tamoxifen therapy from 5 to 10 years significantly reduces the risk of recurrence and breast cancer mortality, according to updated results of the aTTom trial presented by Richard Gray, MD, MSc, of the University of Oxford, United Kingdom.
mTor Inhibition: Small Improvement in PFS in HER2+ Metastatic Breast Cancer in BOLERO-3
June 3, 2013
According to the BOLERO-3 trial, adding everolimus improved survival in patients with HER2+ locally advanced or metastatic trastuzumab-resistant breast cancer.
Η διπλή στόχευση του HER2 τίθεται σε σε αμφιβολία στην προεγχειρητική αντιμετώπιση νεοδιγνωσθέντων Targeting Questioned in Preoperative Treatment of HER2+ καρκίνων μαστού σταδίου II έως III
June 3, 2013
Conclusions from a clinical trial indicate that treatment with trastuzumab and lapatinib for patients with newly diagnosed stage II to III HER2+ breast cancer may not enter into routine use in clinical practice.
In Briefs: Monday
June 3, 2013
Brief summaries of presentations relating to breast cancer, cancer prevention, and more.
Ο κίνδυνος της αμηνόρροιας από τη χημειοθεραπεία σχετίζεται με την ηλικία και τα επίπεδα της αnti-Müllerian ορμόνης πριν τη θεραπεία
June 3, 2013
A woman’s anti-müllerian hormone (AMH) level prior to chemotherapy for breast cancer may be a potential biomarker for her risk of chemotherapy–related amenorrhea (CRA), according to Kathryn J. Ruddy, MD, MPH, at the Dana-Farber Cancer Institute. The quality-of-life substudy of the ECOG5103 trial found that a lower baseline level of the hormone was associated with a higher likelihood of CRA at 18 months (Abstract 9508).
Στην παρακολούθηση των επιζώντων από καρκίνο μαστού, πρώτο μέλημα το μη βλάπτειν
June 3, 2013
An overview of the "Surveillance and Monitoring in Breast Cancer Survivors: Maximizing Benefit and Minimizing Harm" Education Session, which will discuss failure to follow evidence-based practice in caring for breast cancer survivors.
SΣυνεδρίαση διαφωτίζει τις σχέσεις μεταξύ παχυσαρκίας και κινδύνου ανάπτυξης καρκίνου μαστού
June 3, 2013
An overview of the "Obesity and Inflammation: The Dangerous Duo in Breast Cancer" Education Session, which will address the evidence linking obesity and poor outcomes in breast cancer.
Defining the Pathway to Accelerated Drug Approval for Neoadjuvant Therapy
June 2, 2013
Fimal guidance from the FDA on a new approval pathway for neoadjuvant breast cancer drugs will have serious implications for researchers, clinicians, and patients with breast cancer.
EGFR Pathway: Enabling Patient Selection, More Research Needed Regarding Resistance
June 2, 2013
Dr. Karen Reckamp provides an overview of the role of epidermal growth factor receptor (EGFR) overexpression in multiple cancer types, detailing current research and progress on therapeutics that target this pathway.
Dr. Chau Dang: HER2 Pathway's Relevance in Breast Cancer, Emerging Research Across Cancer Types
June 1, 2013
Chau T. Dang, MD, Memorial Sloan-Kettering Cancer Center, provides insight about the HER2 pathway's importance in prognosis and prediction of response in breast cancer. Trials in adjuvant and metastatic settings are discussed, as the HER2 pathway's potential in gastroesophageal, non-small cell lung and urothelial cancers.
Dr. Monica Morrow: Controversy Over FDA's Decision to Allow Neoadjuvant Studies Serve as Pathway to Drug Approval
June 1, 2013
Monica Morrow, MD, discusses the controversial decision by the FDA to allow neoadjuvant studies serve as a pathway to drug approval. Although it might lead to quicker results in these studies, there are concerns over their inability to accurately predict survival and the potential for unexpected toxicities with longer-term drug administration.
ASCO Study Examines Physician Satisfaction, Burnout in Oncology
June 1, 2013
To assess whether the demands and stresses of modern oncology practice contribute to physician burnout, and to identify the personal and professional characteristics related to burnout and career satisfaction, ASCO conducted a national survey of medical oncologists.
2013 ASCO Educational Book Welcomes New Editor, Expands Multimedia Offerings
June 1, 2013
The ASCO Educational Book, a peer-reviewed collection of articles published in conjunction with the Annual Meeting and written by the expert education session faculty, will be indexed in the National Library of Medicine’s MEDLINE database for the first time in 2013. It also has a new editor, Dr. Don S. Dizon.
Innovations in Breast Cancer Drug Development: The Neoadjuvant Breast Cancer Workshop
June 1, 2013
Dr. Patricia Cortazar takes a look at the new agents that can treat breast cancer, and the pros and cons of neoadjuvant trials to support drug approval.
The HER2 Pathway in Breast Cancer
June 1, 2013
Given the early identification of HER2 in breast cancer and the advancement of targeted agents, this disease may serve as a model for development of targeted therapies in solid tumors in general.
Bridging Funding Gaps in Breast Cancer Research
June 1, 2013
Angela R. Bradbury, MD, an assistant professor at the University of Pennsylvania, is the winner of the 2013 Advanced Clinical Research Award in Breast Cancer.
Saima Hassan, MD, PhD, Receives First YIA in Memory of Evelyn H. Lauder
June 1, 2013
Dr. Saima Hassan is the recipient of the very first Evelyn H. Lauder Young Investigator Award (YIA).
2013 Breast Cancer Symposium to Highlight Multidisciplinary Collaboration
June 1, 2013
Each year, the Breast Cancer Symposium brings together specialists from a wide range of disciplines to focus on the importance of understanding and incorporating the latest research to strengthen collaborative breast cancer treatment approaches and, ultimately, to enhance cancer care.
New Resources Strengthen JCO Influence on Readers, Authors
June 1, 2013
Over the past year, JCO has cultivated its outreach and effect on readers, as well as on authors, with the arrival of three new article types and Special Series Issues on caring for the whole patient, comparative effectiveness research, adult survivorship, and non-small cell lung cancer. A new Video Instruction section has also been added to the website.
Conquer Cancer Foundation Supports Young Oncologists with YIA and CDA Grants
June 1, 2013
The YIA provides research funding to promising young physicians during the final years of training to support the transition to a faculty appointment and to encourage quality research in clinical oncology. Similarly, the CDA provides research funding to clinical investigators in the first to third year of faculty appointment to establish an independent clinical research program.
Dr. Karen L. Reckamp: Better Understanding, Targeting of EGFR Pathway Needed
May 31, 2013
Karen L. Reckamp, MD, MS, City of Hope, discusses the way the EGFR pathway acts differently across disease sites, emphasizing the need for a better understanding of inevitable therapeutic resistance and more focused targeting of the pathway itself in various cancer types.
Dr. Matthew J. Ellis: Future of Cancer Genome Atlas Project in Breast Cancer
May 31, 2013
In an exclusive video interview with ASCO Daily News, Matthew J. Ellis, MB, BChir, PhD, Siteman Cancer Center, Washington University School of Medicine, discusses the Cancer Genome Atlas Project to date with regard to breast cancer and the future implications for patients with more advanced stages of disease.
2013 Special Awards and Lectures
May 31, 2013
Each year ASCO recognizes 12 outstanding members of the oncology community who have demonstrated leadership in research and advocacy, a commitment to high-quality patient care, and have made significant contributes to the Society. Here are the 12 Special Awards being presented at this year’s Meeting.
New ASCO University® Curriculum for Advanced Practice Providers
May 31, 2013
ASCO University® has recently begun offering a new curriculum, ASCO’s Curriculum for Advanced Practice Providers (ACAPP™), designed to help practices meet the demand for team-based care and address the growing shortage of health care workers
June 3, 2013
In women with early breast cancer, extending the duration of adjuvant tamoxifen therapy from 5 to 10 years significantly reduces the risk of recurrence and breast cancer mortality, according to updated results of the aTTom trial presented by Richard Gray, MD, MSc, of the University of Oxford, United Kingdom.
mTor Inhibition: Small Improvement in PFS in HER2+ Metastatic Breast Cancer in BOLERO-3
June 3, 2013
According to the BOLERO-3 trial, adding everolimus improved survival in patients with HER2+ locally advanced or metastatic trastuzumab-resistant breast cancer.
Η διπλή στόχευση του HER2 τίθεται σε σε αμφιβολία στην προεγχειρητική αντιμετώπιση νεοδιγνωσθέντων Targeting Questioned in Preoperative Treatment of HER2+ καρκίνων μαστού σταδίου II έως III
June 3, 2013
Conclusions from a clinical trial indicate that treatment with trastuzumab and lapatinib for patients with newly diagnosed stage II to III HER2+ breast cancer may not enter into routine use in clinical practice.
In Briefs: Monday
June 3, 2013
Brief summaries of presentations relating to breast cancer, cancer prevention, and more.
Ο κίνδυνος της αμηνόρροιας από τη χημειοθεραπεία σχετίζεται με την ηλικία και τα επίπεδα της αnti-Müllerian ορμόνης πριν τη θεραπεία
June 3, 2013
A woman’s anti-müllerian hormone (AMH) level prior to chemotherapy for breast cancer may be a potential biomarker for her risk of chemotherapy–related amenorrhea (CRA), according to Kathryn J. Ruddy, MD, MPH, at the Dana-Farber Cancer Institute. The quality-of-life substudy of the ECOG5103 trial found that a lower baseline level of the hormone was associated with a higher likelihood of CRA at 18 months (Abstract 9508).
Στην παρακολούθηση των επιζώντων από καρκίνο μαστού, πρώτο μέλημα το μη βλάπτειν
June 3, 2013
An overview of the "Surveillance and Monitoring in Breast Cancer Survivors: Maximizing Benefit and Minimizing Harm" Education Session, which will discuss failure to follow evidence-based practice in caring for breast cancer survivors.
SΣυνεδρίαση διαφωτίζει τις σχέσεις μεταξύ παχυσαρκίας και κινδύνου ανάπτυξης καρκίνου μαστού
June 3, 2013
An overview of the "Obesity and Inflammation: The Dangerous Duo in Breast Cancer" Education Session, which will address the evidence linking obesity and poor outcomes in breast cancer.
Defining the Pathway to Accelerated Drug Approval for Neoadjuvant Therapy
June 2, 2013
Fimal guidance from the FDA on a new approval pathway for neoadjuvant breast cancer drugs will have serious implications for researchers, clinicians, and patients with breast cancer.
EGFR Pathway: Enabling Patient Selection, More Research Needed Regarding Resistance
June 2, 2013
Dr. Karen Reckamp provides an overview of the role of epidermal growth factor receptor (EGFR) overexpression in multiple cancer types, detailing current research and progress on therapeutics that target this pathway.
Dr. Chau Dang: HER2 Pathway's Relevance in Breast Cancer, Emerging Research Across Cancer Types
June 1, 2013
Chau T. Dang, MD, Memorial Sloan-Kettering Cancer Center, provides insight about the HER2 pathway's importance in prognosis and prediction of response in breast cancer. Trials in adjuvant and metastatic settings are discussed, as the HER2 pathway's potential in gastroesophageal, non-small cell lung and urothelial cancers.
Dr. Monica Morrow: Controversy Over FDA's Decision to Allow Neoadjuvant Studies Serve as Pathway to Drug Approval
June 1, 2013
Monica Morrow, MD, discusses the controversial decision by the FDA to allow neoadjuvant studies serve as a pathway to drug approval. Although it might lead to quicker results in these studies, there are concerns over their inability to accurately predict survival and the potential for unexpected toxicities with longer-term drug administration.
ASCO Study Examines Physician Satisfaction, Burnout in Oncology
June 1, 2013
To assess whether the demands and stresses of modern oncology practice contribute to physician burnout, and to identify the personal and professional characteristics related to burnout and career satisfaction, ASCO conducted a national survey of medical oncologists.
2013 ASCO Educational Book Welcomes New Editor, Expands Multimedia Offerings
June 1, 2013
The ASCO Educational Book, a peer-reviewed collection of articles published in conjunction with the Annual Meeting and written by the expert education session faculty, will be indexed in the National Library of Medicine’s MEDLINE database for the first time in 2013. It also has a new editor, Dr. Don S. Dizon.
Innovations in Breast Cancer Drug Development: The Neoadjuvant Breast Cancer Workshop
June 1, 2013
Dr. Patricia Cortazar takes a look at the new agents that can treat breast cancer, and the pros and cons of neoadjuvant trials to support drug approval.
The HER2 Pathway in Breast Cancer
June 1, 2013
Given the early identification of HER2 in breast cancer and the advancement of targeted agents, this disease may serve as a model for development of targeted therapies in solid tumors in general.
Bridging Funding Gaps in Breast Cancer Research
June 1, 2013
Angela R. Bradbury, MD, an assistant professor at the University of Pennsylvania, is the winner of the 2013 Advanced Clinical Research Award in Breast Cancer.
Saima Hassan, MD, PhD, Receives First YIA in Memory of Evelyn H. Lauder
June 1, 2013
Dr. Saima Hassan is the recipient of the very first Evelyn H. Lauder Young Investigator Award (YIA).
2013 Breast Cancer Symposium to Highlight Multidisciplinary Collaboration
June 1, 2013
Each year, the Breast Cancer Symposium brings together specialists from a wide range of disciplines to focus on the importance of understanding and incorporating the latest research to strengthen collaborative breast cancer treatment approaches and, ultimately, to enhance cancer care.
New Resources Strengthen JCO Influence on Readers, Authors
June 1, 2013
Over the past year, JCO has cultivated its outreach and effect on readers, as well as on authors, with the arrival of three new article types and Special Series Issues on caring for the whole patient, comparative effectiveness research, adult survivorship, and non-small cell lung cancer. A new Video Instruction section has also been added to the website.
Conquer Cancer Foundation Supports Young Oncologists with YIA and CDA Grants
June 1, 2013
The YIA provides research funding to promising young physicians during the final years of training to support the transition to a faculty appointment and to encourage quality research in clinical oncology. Similarly, the CDA provides research funding to clinical investigators in the first to third year of faculty appointment to establish an independent clinical research program.
Dr. Karen L. Reckamp: Better Understanding, Targeting of EGFR Pathway Needed
May 31, 2013
Karen L. Reckamp, MD, MS, City of Hope, discusses the way the EGFR pathway acts differently across disease sites, emphasizing the need for a better understanding of inevitable therapeutic resistance and more focused targeting of the pathway itself in various cancer types.
Dr. Matthew J. Ellis: Future of Cancer Genome Atlas Project in Breast Cancer
May 31, 2013
In an exclusive video interview with ASCO Daily News, Matthew J. Ellis, MB, BChir, PhD, Siteman Cancer Center, Washington University School of Medicine, discusses the Cancer Genome Atlas Project to date with regard to breast cancer and the future implications for patients with more advanced stages of disease.
2013 Special Awards and Lectures
May 31, 2013
Each year ASCO recognizes 12 outstanding members of the oncology community who have demonstrated leadership in research and advocacy, a commitment to high-quality patient care, and have made significant contributes to the Society. Here are the 12 Special Awards being presented at this year’s Meeting.
New ASCO University® Curriculum for Advanced Practice Providers
May 31, 2013
ASCO University® has recently begun offering a new curriculum, ASCO’s Curriculum for Advanced Practice Providers (ACAPP™), designed to help practices meet the demand for team-based care and address the growing shortage of health care workers
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου